文献速递炎症性肠病

GPR171通过抑制FABP5介导的Th17细胞分化和脂质代谢来限制肠道炎症

GPR171 restrains intestinal inflammation by suppressing FABP5-mediated Th17 cell differentiation and lipid metabolism.
PubMed 文献 · Gut · 2025-07-07

本研究探讨GPR171在炎症性肠病(IBD)中调节CD4+ T细胞效应的作用及治疗潜力。分析IBD患者结肠活检和外周血样本,并通过给予内源性配体BigLEN评估GPR171对CD4+ T细胞分化的影响。在DSS诱导结肠炎和CD45RBhighCD4+ T细胞转移结肠炎模型中确定GPR171的作用,并用RNA测序和脂质组学阐明机制。开发基于BigLEN的Fc融合蛋白(BigLEN-Fc)并评估其预防和治疗结肠炎的潜力。

要点

  • GPR171在IBD患者炎症黏膜和CD4+ T细胞中较对照显著增加。
  • BigLEN触发的GPR171激活在体外抑制Th17细胞分化。
  • GPR171缺陷通过cAMP-pCREB-FABP5轴促进Th17细胞分化和脂质代谢扰动,加重小鼠结肠炎。

核心结论

  • GPR171缺陷以FABP5依赖的方式促进Th17细胞分化并引起脂质代谢扰动,导致肠道炎症。
  • 靶向治疗(如BigLEN-Fc)代表一种新的IBD治疗方法。

研究设计与样本

  • 分析IBD患者结肠活检和外周血样本中GPR171表达。
  • 通过给予内源性配体BigLEN评估GPR171对CD4+ T细胞分化的影响。
  • 在DSS诱导结肠炎和CD45RBhighCD4+ T细胞转移结肠炎模型中确定GPR171的作用。
  • 使用RNA测序和脂质组学解析机制。
  • 开发新型基于BigLEN的Fc融合蛋白(BigLEN-Fc)并评估其预防和治疗结肠炎的潜力。

主要发现

  • GPR171在IBD患者炎症黏膜和CD4+ T细胞中较对照显著增加。
  • BigLEN触发的GPR171激活在体外抑制Th17细胞分化。
  • GPR171缺陷加重DSS诱导和CD45RBhighCD4+ T细胞诱导的小鼠结肠炎,特征为肠黏膜Th17细胞反应增加。
  • 机制上,GPR171缺陷通过cAMP-pCREB-FABP5轴促进Th17细胞分化并改变Th17细胞脂质组谱。
  • 阻断FABP5在体外减少Th17细胞分化并改善Gpr171-/-小鼠的DSS诱导结肠炎。

临床怎么用

  • 作者认为靶向治疗(如BigLEN-Fc)代表一种新的IBD治疗方法。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: GPR171 suppresses T cell immune responses involved in antitumour immunity, while its role in inflammatory bowel disease (IBD) pathogenesis remains unclear. OBJECTIVE: We aimed to investigate the role of GPR171 in modulating CD4+ T cell effector functions in IBD and evaluate its therapeutic potential. DESIGN: We analysed GPR171 expression in colon biopsies and peripheral blood samples from patients with IBD and assessed the impact of GPR171 on CD4+ T cell differentiation through administration of its endogenous ligand (BigLEN). We further determined the role of GPR171 in dextran sulfate sodium (DSS)-induced colitis and CD45RBhighCD4+ T-cell transfer colitis model and deciphered the underlying mechanisms using RNA sequencing (RNA-seq) and lipidomics. We developed a novel BigLEN-based Fc fusion protein (BigLEN-Fc) and evaluated its potential in preventing and treating colitis. RESULTS: GPR171 was markedly increased in inflamed mucosa and CD4+ T cells of patients with IBD compared with controls. BigLEN-triggered GPR171 activation inhibited Th17 cell differentiation in vitro. GPR171 deficiency exacerbated DSS- and CD45RBhighCD4+ T cell-induced colitis in mice, characterised by increased Th17 cell responses in intestinal mucosa. Mechanistically, GPR171 deficiency promoted Th17 cell differentiation and altered lipidome profile in Th17 cells via the cAMP-pCREB-FABP5 axis. Blockage of FABP5 reduced Th17 cell differentiation in vitro and ameliorated DSS-induced colitis in Gpr171 -/- mice. Furthermore, BigLEN-mutFc administration potently mitigated colitis in mice. CONCLUSIONS: GPR171 deficiency promotes Th17 cell differentiation and causes lipid metabolism perturbation, contributing to intestinal inflammation in a FABP5-dependent manner. Target therapy (eg, BigLEN-Fc) represents a novel therapeutic approach for IBD treatment.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Kou F, Li XY, Feng Z, et al. GPR171 restrains intestinal inflammation by suppressing FABP5-mediated Th17 cell differentiation and lipid metabolism. Gut. 2025. PMID: 40074327. doi:10.1136/gutjnl-2024-334010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。